One injection every six months instead of constant treatment
No Brasil, a Anvisa aprovou na quarta-feira o DENSURKO (depemoquimabe), um novo medicamento injetável destinado a pacientes com asma grave eosinofílica e rinossinusite crônica com pólipos nasais a partir dos 12 anos. A aprovação responde a uma necessidade clínica real: pessoas cujas vias aéreas travam em um ciclo inflamatório específico, resistente às terapias convencionais, enfrentavam opções terapêuticas historicamente limitadas. Com uma única injeção a cada seis meses, o medicamento não apenas amplia o arsenal médico, mas também alivia o peso cotidiano de quem gerencia uma doença crônica grave.
- Pacientes com asma grave eosinofílica vivem sob a ameaça constante de crises que podem resultar em internações ou situações de risco de vida.
- A inflamação do tipo 2, marcada pelo excesso de eosinófilos, não responde bem aos tratamentos padrão, deixando adultos e adolescentes em um limbo terapêutico perigoso.
- A Anvisa aprovou o DENSURKO como tratamento complementar, abrindo uma nova frente de combate sem substituir as terapias já em curso.
- A dosagem semestral reduz drasticamente a frequência de visitas clínicas, tornando o tratamento mais compatível com a rotina de estudantes, trabalhadores e cuidadores.
- A aprovação simultânea para rinossinusite crônica com pólipos nasais significa que muitos pacientes — que sofrem das duas condições ao mesmo tempo — podem simplificar seus esquemas terapêuticos com um único medicamento.
A Anvisa aprovou na última quarta-feira, 13 de maio, o DENSURKO (depemoquimabe), medicamento injetável voltado para um tipo específico e sério de asma: aquela impulsionada por inflamação do tipo 2, caracterizada pelo acúmulo excessivo de eosinófilos nas vias aéreas. Para esses pacientes — adultos e adolescentes a partir dos 12 anos — as opções terapêuticas sempre foram escassas, e o risco de crises graves, uma presença constante.
O medicamento funciona como tratamento complementar, atuando ao lado de outras terapias já em uso. Seu diferencial mais imediato é prático: uma única injeção a cada seis meses. Para quem convive com uma doença crônica, esse intervalo longo entre doses representa menos deslocamentos, menos procedimentos e menos interrupções na vida cotidiana — um alívio concreto para quem equilibra tratamento com trabalho, escola ou responsabilidades familiares.
A aprovação também contempla a rinossinusite crônica com pólipos nasais, condição inflamatória dos seios nasais que frequentemente coexiste com a asma grave. Muitos pacientes sofrem das duas doenças simultaneamente, com inflamação que se estende do nariz aos pulmões. Um único medicamento capaz de atuar em ambas as frentes simplifica esquemas de tratamento que, de outra forma, exigiriam múltiplos fármacos com efeitos colaterais e horários sobrepostos.
Ao agir sobre uma via inflamatória específica — em vez de suprimir o sistema imunológico de forma ampla —, o DENSURKO apresenta um perfil de segurança distinto das abordagens mais antigas. Para o sistema de saúde brasileiro, a aprovação representa acesso a uma geração mais precisa de tratamentos imunológicos, oferecendo a médicos e pacientes uma nova ferramenta para prevenir crises antes que elas aconteçam.
Brazil's health regulator cleared a new weapon against severe asthma on Wednesday, May 13th. The Anvisa—the National Health Surveillance Agency—announced approval of DENSURKO, a medication whose chemical name is depemoquimabe, for patients whose airways are locked in a particular kind of inflammatory battle. The drug arrives as an injectable solution, delivered through a pre-filled syringe or pen applicator, ready to use straight from the box.
The condition it targets is specific and serious. Some people with asthma don't respond well to standard treatments because their inflammation runs on a type-2 pathway—the allergic kind—marked by an excess of eosinophils, white blood cells that swarm the airways and trigger dangerous flare-ups. For these patients, the risk of severe asthma attacks looms larger than for others. DENSURKO works as a complementary treatment, meaning it works alongside other therapies rather than replacing them entirely. It's designed for adults and children aged twelve and older.
The dosing schedule is straightforward: one injection every six months. This long interval between doses matters for patients managing a chronic condition. It means fewer trips to clinics, fewer needle sticks, fewer moments of disruption in daily life. For someone juggling school, work, or family responsibilities while managing a serious respiratory disease, that spacing can mean the difference between a treatment plan that fits into life and one that constantly interrupts it.
The approval represents an expansion of options for a population that has historically faced limited choices. Severe asthma with eosinophilic inflammation is not common, but for those who have it, the stakes are high. An uncontrolled attack can land someone in an emergency room, in a hospital bed, or worse. The addition of DENSURKO to the treatment arsenal gives doctors and patients another tool to prevent those crises before they happen.
The same medication also carries approval for treating chronic rhinosinusitis with nasal polyps—a separate but related condition where inflammation in the sinuses and nasal passages creates growths that block breathing and drainage. Many patients suffer from both conditions simultaneously, their airways inflamed from nose to lungs. A single medication that addresses both represents a meaningful simplification of treatment regimens that might otherwise require multiple drugs with overlapping side effects and dosing schedules.
For the Brazilian healthcare system, the approval signals continued access to cutting-edge immunological treatments. DENSURKO targets the specific inflammatory pathway rather than suppressing the immune system broadly, which means it carries a different safety profile than older, blunter approaches. Patients and their doctors now have the information they need to decide whether this option makes sense for their particular situation.
Citações Notáveis
The product is indicated as complementary treatment for asthma in adult and pediatric patients aged 12 and older with type-2 inflammation characterized by excess eosinophils in the blood— Anvisa
A Conversa do Hearth Outra perspectiva sobre a história
Why does the timing of this approval matter right now, in May 2026?
It doesn't matter because of the date itself, but because patients with severe eosinophilic asthma have been waiting. The approval means they can stop hoping for something better and start accessing it.
You mentioned the six-month dosing interval as if it were significant. Isn't that just a detail?
It's not just a detail—it's the difference between a treatment you can live with and one that dominates your life. Imagine needing an injection every month versus every six months. One becomes routine; the other becomes a constant negotiation with your schedule.
What makes type-2 inflammation different from other kinds of asthma inflammation?
Type-2 is the allergic pathway. Your immune system is overreacting to something—pollen, dust, an allergen—and eosinophils are the foot soldiers doing the damage. Other asthmas work differently. This drug speaks the language of type-2 specifically.
Does this drug cure asthma?
No. It's complementary, which means it works alongside other treatments. It reduces the risk of severe attacks, but it doesn't erase the condition. For someone with severe asthma, reducing that risk of a crisis is often enough.
Who benefits most from this approval?
Adults and teenagers with severe asthma driven by eosinophilic inflammation, and people whose sinuses are clogged with polyps from the same inflammatory process. If you're managing both conditions, this becomes even more valuable—one drug addressing two problems.
What happens next for patients who might need this?
They talk to their doctor. They get tested to confirm they have the right kind of inflammation. If they do, they can discuss whether DENSURKO fits their situation. The approval means it's now an option on the table.